TuisSGEN • BMV
add
Seagen
Vorige sluiting
$3 711,48
Jaarwisseling
$3 711,48 - $3 711,48
Markkapitalisasie
43,15 mjd USD
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2023info | J/J-verandering |
---|---|---|
Inkomste | 648,65 m | 27,11% |
Bedryfskoste | 262,69 m | 24,86% |
Netto inkomste | -215,79 m | -13,09% |
Netto winsgrens | -33,27 | 11,02% |
Wins per aandeel | -1,15 | -11,65% |
EBITDA | -209,33 m | -19,47% |
Effektiewe belastingkoers | 0,26% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2023info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 1,24 mjd | -29,86% |
Totale bates | 3,63 mjd | 0,42% |
Totale aanspreeklikheid | 1,08 mjd | 35,94% |
Totale ekwiteit | 2,55 mjd | — |
Uitstaande aandele | 188,66 m | — |
Prys om te bespreek | 274,52 | — |
Opbrengs op bates | -16,01% | — |
Opbrengs op kapitaal | -21,12% | — |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2023info | J/J-verandering |
---|---|---|
Netto inkomste | -215,79 m | -13,09% |
Kontant van bedrywe | -35,82 m | 58,21% |
Kontant van beleggings | 142,49 m | 119,31% |
Kontant van finansiering | 15,52 m | -15,59% |
Netto kontantverandering | 119,90 m | 1 958,05% |
Beskikbare kontantvloei | 71,52 m | 1 141,10% |
Meer oor
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Gestig
15 Jul. 1997
Hoofkwartier
Webwerf
Werknemers
3 256